164 related articles for article (PubMed ID: 21994351)
1. Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.
Schuerman L; Wysocki J; Tejedor JC; Knuf M; Kim KH; Poolman J
Clin Vaccine Immunol; 2011 Dec; 18(12):2161-7. PubMed ID: 21994351
[TBL] [Abstract][Full Text] [Related]
2. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
5. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
[TBL] [Abstract][Full Text] [Related]
6. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children.
Henckaerts I; Durant N; De Grave D; Schuerman L; Poolman J
Vaccine; 2007 Mar; 25(13):2518-27. PubMed ID: 17034907
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
Madhi SA; Izu A; Violari A; Cotton MF; Panchia R; Dobbels E; Sewraj P; van Niekerk N; Jean-Philippe P; Adrian PV;
Vaccine; 2013 Jan; 31(5):777-83. PubMed ID: 23228814
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.
Silfverdal SA; Hogh B; Bergsaker MR; Skerlikova H; Lommel P; Borys D; Schuerman L
Pediatr Infect Dis J; 2009 Oct; 28(10):e276-82. PubMed ID: 20118683
[TBL] [Abstract][Full Text] [Related]
9. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.
Russell FM; Carapetis JR; Burton RL; Lin J; Licciardi PV; Balloch A; Tikoduadua L; Waqatakirewa L; Cheung YB; Tang ML; Nahm MH; Mulholland EK
Vaccine; 2011 Jan; 29(3):535-44. PubMed ID: 21044669
[TBL] [Abstract][Full Text] [Related]
10. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
13. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.
Simell B; Nurkka A; Ekström N; Givon-Lavi N; Käyhty H; Dagan R
Clin Vaccine Immunol; 2012 Oct; 19(10):1618-23. PubMed ID: 22875604
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
[TBL] [Abstract][Full Text] [Related]
15. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.
Frenck RW; Gurtman A; Rubino J; Smith W; van Cleeff M; Jayawardene D; Giardina PC; Emini EA; Gruber WC; Scott DA; Schmöle-Thoma B
Clin Vaccine Immunol; 2012 Aug; 19(8):1296-303. PubMed ID: 22739693
[TBL] [Abstract][Full Text] [Related]
16. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
[TBL] [Abstract][Full Text] [Related]
18. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.
Lee H; Nahm MH; Burton R; Kim KH
Clin Vaccine Immunol; 2009 Mar; 16(3):376-81. PubMed ID: 19144787
[TBL] [Abstract][Full Text] [Related]
19. Association of serotype-specific antibody concentrations and functional antibody titers with subsequent pneumococcal carriage in toddlers immunized with a 9-valent pneumococcal conjugate vaccine.
Simell B; Nurkka A; Lahdenkari M; Givon-Lavi N; Käyhty H; Dagan R; Jokinen J
Clin Vaccine Immunol; 2012 Jan; 19(1):96-9. PubMed ID: 22072724
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.
Tan CY; Immermann FW; Sebastian S; Pride MW; Pavliakova D; Belanger KA; Watson W; Scott DA; Sidhu M; Jansen KU; Giardina PC
mSphere; 2018 Aug; 3(4):. PubMed ID: 30089644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
